Related Experiment Video
Updated: May 19, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.
Yuyang Song1,2,3, Thanh Hung Nguyen1,2,3, Pengkai Shi1,2,3
1Molecular Imaging and Nanotherapeutics Laboratory (Y.S., T.H.N., P.S., A.R., C.V.P., B.X., S.R., A.N., H.L., M.L.P.V., X.W.), Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Circulation Research
|May 18, 2026
Summary
New mRNA therapeutics offer safe and effective antithrombotic protection, preventing thrombosis without increasing bleeding risks. This strategy provides long-lasting protection against cardiovascular events.
Area of Science:
- Cardiovascular Medicine
- Biotechnology
- Pharmacology
Background:
- Thrombosis is a leading cause of death in cardiovascular diseases.
- Current antiplatelet drugs carry a risk of systemic bleeding.
- A previously developed single-chain variable fragment (scFv) targets activated platelet integrin αIIbβ3, preventing thrombosis without impairing hemostasis.
Purpose of the Study:
- To develop and evaluate mRNA-based therapeutics encoding scFvαIIbβ3 for prolonged antithrombotic expression and durability.
- To assess the safety and efficacy of mRNA-delivered scFvαIIbβ3 in vivo.
Main Methods:
- Designed and synthesized conventional and self-amplifying mRNA constructs encoding scFvαIIbβ3.
- Validated mRNA expression and scFvαIIbβ3 functionality in vitro.
- Delivered mRNA systemically using a novel lipid nanoparticle formulation (OryKL) in a murine thrombosis model.
- Assessed biosafety through biochemical and histological examinations.
Main Results:
- In vitro assays confirmed functional scFvαIIbβ3 expression, secretion, and inhibition of platelet aggregation.
- OryKL-delivered scFvαIIbβ3 mRNA significantly prolonged arterial occlusion time in mice.
- Self-amplifying mRNA provided sustained thromboprotection for over 7 days.
- No significant changes in tail bleeding times or observed systemic toxicity.
Conclusions:
- mRNA therapeutics encoding scFvαIIbβ3 provide safe, effective, and long-acting antithrombotic protection.
- This approach offers a promising alternative to current antiplatelet therapies by mitigating bleeding risks.
- The developed mRNA strategy holds potential for advanced thromboprophylaxis.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...